210 related articles for article (PubMed ID: 15515406)
41. 5-HT3 receptor antagonists for the treatment of nausea/vomiting.
Smith HS; Cox LR; Smith EJ
Ann Palliat Med; 2012 Jul; 1(2):115-20. PubMed ID: 25841471
[TBL] [Abstract][Full Text] [Related]
42. Role of 5-hydroxytryptamine3 (5-HT3) antagonists in the prevention of emesis caused by anticancer therapy.
Karim F; Roerig SC; Saphier D
Biochem Pharmacol; 1996 Sep; 52(5):685-92. PubMed ID: 8765466
[TBL] [Abstract][Full Text] [Related]
43. [Serotonin (5-HT)3 receptors: antagonists and their pharmacological profiles].
Miyata K; Honda K
Nihon Yakurigaku Zasshi; 1994 Sep; 104(3):143-52. PubMed ID: 7959407
[TBL] [Abstract][Full Text] [Related]
44. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications.
Wilde MI; Markham A
Drugs; 1996 Nov; 52(5):773-94. PubMed ID: 9118822
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic potential of drugs with mixed 5-HT4 agonist/5-HT3 antagonist action in the control of emesis.
Tonini M; Candura SM; Messori E; Rizzi CA
Pharmacol Res; 1995 May; 31(5):257-60. PubMed ID: 7479521
[TBL] [Abstract][Full Text] [Related]
46. Immunomodulatory function of the 5-HT3 receptor antagonist tropisetron.
Schneider EM; Ma X; Stratz T; Müller W; Lorenz I; Seeling WD
Scand J Rheumatol Suppl; 2004; 119():34-40. PubMed ID: 15515411
[TBL] [Abstract][Full Text] [Related]
47. Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.
Machu TK
Pharmacol Ther; 2011 Jun; 130(3):338-47. PubMed ID: 21356241
[TBL] [Abstract][Full Text] [Related]
48. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.
Müller W; Stratz T
Scand J Rheumatol Suppl; 2004; 119():44-8. PubMed ID: 15515413
[TBL] [Abstract][Full Text] [Related]
49. Local-anesthetic like inhibition of the cardiac sodium channel Nav1.5 α-subunit by 5-HT3 receptor antagonists.
Van't Klooster MP; Foadi N; Hage A; Stoetzer C; Wegner F; Eberhardt M; Leffler A
Eur J Pharmacol; 2016 Oct; 789():119-126. PubMed ID: 27401036
[TBL] [Abstract][Full Text] [Related]
50. 5-HT3-receptor antagonists and the cytochrome P450 system: clinical implications.
Blower PR
Cancer J; 2002; 8(5):405-14. PubMed ID: 12416899
[TBL] [Abstract][Full Text] [Related]
51. Potential Roles of 5-HT
Satiamurthy R; Yaakob NS; Shah NM; Azmi N; Omar MS
Curr Mol Med; 2023; 23(4):341-349. PubMed ID: 35549869
[TBL] [Abstract][Full Text] [Related]
52. Current experience with 5-HT3 receptor antagonists in fibromyalgia.
Späth M
Rheum Dis Clin North Am; 2002 May; 28(2):319-28. PubMed ID: 12122920
[TBL] [Abstract][Full Text] [Related]
53. The physiology and pharmacology of postoperative nausea and vomiting.
Naylor RJ; Inall FC
Anaesthesia; 1994 Jan; 49 Suppl():2-5. PubMed ID: 8129158
[TBL] [Abstract][Full Text] [Related]
54. Tropisetron, a new 5-HT3 receptor antagonist, in the prevention of irradiation-induced nausea, vomiting and diarrhoea.
Sorbe B; Berglind AM; De Bruijn K
Eur J Gynaecol Oncol; 1992; 13(5):382-9. PubMed ID: 1486916
[TBL] [Abstract][Full Text] [Related]
55. 5-HT3 receptors.
Costall B; Naylor RJ
Curr Drug Targets CNS Neurol Disord; 2004 Feb; 3(1):27-37. PubMed ID: 14965242
[TBL] [Abstract][Full Text] [Related]
56. Natural compounds boldine and menthol are antagonists of human 5-HT3 receptors: implications for treating gastrointestinal disorders.
Walstab J; Wohlfarth C; Hovius R; Schmitteckert S; Röth R; Lasitschka F; Wink M; Bönisch H; Niesler B
Neurogastroenterol Motil; 2014 Jun; 26(6):810-20. PubMed ID: 24708203
[TBL] [Abstract][Full Text] [Related]
57. The effect of ondansetron on radiation-induced emesis and diarrhoea.
Henriksson R; Lomberg H; Israelsson G; Zackrisson B; Franzén L
Acta Oncol; 1992; 31(7):767-9. PubMed ID: 1476756
[TBL] [Abstract][Full Text] [Related]
58. Recent advances with 5-HT
Juza R; Vlcek P; Mezeiova E; Musilek K; Soukup O; Korabecny J
Med Res Rev; 2020 Sep; 40(5):1593-1678. PubMed ID: 32115745
[TBL] [Abstract][Full Text] [Related]
59. Closing remarks. Ondansetron: effects on gastrointestinal motility.
Lamers CB
Scand J Gastroenterol Suppl; 1991; 188():124-6. PubMed ID: 1837938
[TBL] [Abstract][Full Text] [Related]
60. Development of potent serotonin-3 (5-HT3) receptor antagonists. II. Structrue-activity relationships of N-(1-benzyl-4-methylhexahydro-1H-1,4- diazepin-6-yl)carboxamides.
Harada H; Morie T; Hirokawa Y; Terauchi H; Fujiwara I; Yoshida N; Kato S
Chem Pharm Bull (Tokyo); 1995 Nov; 43(11):1912-30. PubMed ID: 8575032
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
